Nasdaq · Healthcare
INSMED Inc (INSM)
As-reported financials and recent SEC filings for INSMED Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$606.4M
Net income
$-1.28B
Net margin
—
Diluted EPS
$-6.42
ROE
-172.8%
P/E (TTM)
—
Market cap
$22.41B
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M |
| Gross profit | $483.5M | $278.0M | $239.6M | $190.2M | $144.3M |
| Operating income | $-1.25B | $-878.3M | $-709.6M | $-457.3M | $-375.1M |
| Net income | $-1.28B | $-913.8M | $-749.6M | $-481.5M | $-434.7M |
| Diluted EPS | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →42026-06-24
View on EDGAR →32026-06-24
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-10
View on EDGAR →1442026-06-08
View on EDGAR →Go deeper on INSM
Search INSMED Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.